Nonproliferative Diabetic Retinopathy Clinical Trial
Official title:
A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy
The primary objective of the study is to assess the efficacy of intravitreal (IVT)
aflibercept compared to sham treatment in the improvement of moderately severe to severe
nonproliferative diabetic retinopathy (NPDR).
The secondary objectives of the study are:
- To characterize the safety of IVT aflibercept in patients with moderately severe to
severe NPDR
- To determine if IVT aflibercept will prevent the worsening of diabetic retinopathy and
reduce the incidence of DME
- To determine the anatomic effects of IVT aflibercept in patients with moderately severe
to severe NPDR
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03197870 -
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
|
Phase 2 | |
| Recruiting |
NCT05383209 -
Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)
|
Phase 2 | |
| Completed |
NCT02834663 -
Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy
|
Phase 4 |